Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV) is a novel coronavirus that causes a highly contagious respiratory disease, SARS, with significant mortality. Although factors contributing to the highly pathogenic nature of SARS-CoV remain poorly understood, it has been reported that SARS-CoV infection does not induce type I interferons (IFNs) in cell culture. However, it is uncertain whether SARS-CoV evades host detection or has evolved mechanisms to counteract innate host defenses. We show here that infection of SARS-CoV triggers a weak IFN response in cultured human lung/bronchial epithelial cells without inducing the phosphorylation of IFN-regulatory factor 3 (IRF-3), a latent cellular transcription factor that is pivotal for type I IFN synthesis. Furthermore, SARS-CoV infection blocked the induction of IFN antiviral activity and the up-regulation of protein expression of a subset of IFN-stimulated genes triggered by double-stranded RNA or an unrelated paramyxovirus. In searching for a SARS-CoV protein capable of counteracting innate immunity, we identified the papain-like protease (PLpro) domain as a potent IFN antagonist. The inhibition of the IFN response does not require the protease activity of PLpro. Rather, PLpro interacts with IRF-3 and inhibits the phosphorylation and nuclear translocation of IRF-3, thereby disrupting the activation of type I IFN responses through either Toll-like receptor 3 or retinoic acid-inducible gene I/melanoma differentiation-associated gene 5 pathways. Our data suggest that regulation of IRF-3-dependent innate antiviral defenses by PLpro may contribute to the establishment of SARS-CoV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(ii) the papain‐like protease domain of CoV‐NL63 binds BECN1 and STING1, thus hindering BECN1‐mediated autophagosome formation and inhibiting IFN production (Devaraj et al, 2007; Chen et al, 2014)”
From Autophagy in major human diseases (2021) · cites this paper as Devaraj et al, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 3,929
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006) · Nature · doi:10.1038/nature04734 · Cited by 3,888
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Seth, R. B., Sun, L., Ea, C.-K., & Chen, Z. J. (2005) · Cell · doi:10.1016/j.cell.2005.08.012 · Cited by 3,329
Self-citationIKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K. J., Takeuchi, O., & Akira, S. (2005) · Nature Immunology · doi:10.1038/ni1243 · Cited by 2,562
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Cited by
Items 201–300 of 413
Shi, X., Wang, L., Zhi, Y., Xing, G., Zhao, D. Q., Deng, R., & Zhang, G. (2010) · Virus Research · doi:10.1016/j.virusres.2010.07.028 · Cited by 40
“Many viruses developed defensive mechanisms to inhibit IFN- production (Bowie and Unterholzner, 2008; Devaraj et al., 2007; Weber et al., 2004).”
InfluentialMurine Coronavirus Delays Expression of a Subset of Interferon-Stimulated Genes
Rose, K. M., Elliott, R., Martínez‐Sobrido, L., García‐Sastre, A., & Weiss, S. R. (2010) · Journal of Virology · doi:10.1128/jvi.00211-10 · Cited by 42
Ebselen as a highly active inhibitor of PL Pro CoV2Preprint
Węglarz‐Tomczak, E., Tomczak, J. M., Talma, M., & Brul, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.17.100768 · Cited by 39
Chen, N., Jin, J., Zhang, B., Meng, Q., Lu, Y., Liang, B., Deng, L., Qiao, B., & Zheng, L. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2341144 · Cited by 42
“Mechanistically, IAV(PA) and SARS-CoV(PLpro) reduce IFN-β expression by inhibiting IRF3 phosphorylation [43,44].”
BackgroundTemeeyasen, G., Sinha, A. S., Gimenez-Lirola, L. G., Zhang, J., & Piñeyro, P. E. (2017) · Virology · doi:10.1016/j.virol.2017.11.024 · Cited by 40
“The non-canonical pathway is TLRindependent, and NF-κB can be modulated by RIG-I-TRAF3 mediated through IRF3 (Devaraj et al., 2007).”
BackgroundDaczkowski, C. M., Goodwin, O. Y., Dzimianski, J. V., Farhat, J. J., & Pegan, S. D. (2017) · Journal of Virology · doi:10.1128/jvi.01067-17 · Cited by 36
“to be a key viral evasion mechanism (15, 16).”
BackgroundVirus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19
Zhang, J., Zhao, C., & Zhao, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633769 · Cited by 43
“As a crucial adaptor of the antiviral signaling pathway, IRF3 is also a key target of multiple SARS proteins including PLpro, N, ORF3b, and ORF6 protein (Figure 2) (56, 57).”
BackgroundTherapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection
Maity, S., & Saha, A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.675419 · Cited by 35
Kalra, R. S., Dhanjal, J. K., Meena, A. S., Kalel, V. C., Dahiya, S., Singh, B., Dewanjee, S., & Kandimalla, R. J. L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.662786 · Cited by 38
Murine Coronavirus Cell Type Dependent Interaction with the Type I Interferon Response
Rose, K. M., & Weiss, S. R. (2009) · Viruses · doi:10.3390/v1030689 · Cited by 35
“[78] concluded that PLP interacts physically with IRF3 to inhibit phosphorylation, dimerization and nuclear import, Frieman et al.”
BackgroundSchroeder, S., Mache, C., Kleine‐Weber, H., Corman, V. M., Muth, D., Richter, A. M., Fatykhova, D., Memish, Z. A., Stanifer, M. L., Boulant, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25519-1 · Cited by 34
Human coronaviruses: Clinical features and phylogenetic analysis
Li, S.-W., & Lin, C. (2013) · Biomedicine · doi:10.1016/j.biomed.2012.12.007 · Cited by 34
“In addition, clinical laboratory tests have shown that patients with SARS often present with thrombocytopenia and leukopenia [51,52] as well as overexpression of serum inflammatory cytokines, including interferon (IFN)-g, interleukin (IL)-18, transforming ’-terminal 2/3 gene of the coronavirus and encode two he four s…”
BackgroundInfluentialAdvances in Antiviral Therapies Targeting Toll-like Receptors
Shah, M., Anwar, M. A., Kim, J., & Choi, S. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1154040 · Cited by 37
“SARSCoV PLpro IRF3 Hinders activation [80] PLpro TRAF6, TBK1 Removal of ubiquitin tag from target protein [92]”
Deng, X., Mettelman, R. C., O’Brien, A., Thompson, J. A., O’Brien, T. E., & Baker, S. C. (2019) · Journal of Virology · doi:10.1128/jvi.02140-18 · Cited by 32
“Viral DUB activity has been implicated as a modulator of the innate immune response to viral infection (32, 34, 35) , but the target(s) of the DUB activity has not yet been identified.”
BackgroundResultSelf-citationDeng, X., Chen, Y., Mielech, A. M., Hackbart, M., Kesely, K. R., Mettelman, R. C., O’Brien, A., Chapman, M. E., Mesecar, A. D., & Baker, S. C. (2020) · Journal of Virology · doi:10.1128/jvi.01734-19 · Cited by 32
“In agreement with previous reports (13, 25, 31), we find that 158”
ResultSelf-citationCoronavirus in human diseases: Mechanisms and advances in clinical treatment
Lin, P., Wang, M., Wei, Y., Kim, T., & Wei, X. (2020) · MedComm · doi:10.1002/mco2.26 · Cited by 37
García-del-Barco, D., Risco-Acevedo, D., Berlanga‐Acosta, J., Martos-Benítez, F. D., & Guillén, G. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655528 · Cited by 37
Zhou, P., Li, H., Wang, H., Wang, L., & Shi, Z. (2011) · Journal of General Virology · doi:10.1099/vir.0.033589-0 · Cited by 31
“Severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2003 and caused widespread mortality in humans, encodes at least five proteins that function as IFN antagonists (Devaraj et al., 2007; Kamitani et al., 2006; Kopecky-Bromberg et al., 2007), suppressing components of both signalling and producti…”
BackgroundInfluentialNucleic Acid-Sensing Pathways During SARS-CoV-2 Infection: Expectations versus Reality
Mdkhana, B., Sharif‐Askari, N. S., Ramakrishnan, R. K., Goel, S., Hamid, Q. A., & Halwani, R. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s277716 · Cited by 32
High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
Zang, Y., Su, M., Wang, Q., Cheng, X., Zhang, W., Zhao, Y., Chen, T., Jiang, Y., Shen, Q., Du, J., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac016 · Cited by 34
“…maturation (Baez-Santos et al. 2015), and participate in inhibiting the production of cytokines and chemokines, which are crucial in the host innate immune response against viral infection (Devaraj et al. 2007; Frieman et al. 2009; Clementz et al. 2010; Calistri et al. 2014; Mielech et al. 2014).”
BackgroundCOVID-19: The Emerging Immunopathological Determinants for Recovery or Death
Ahmad, T., Chaudhuri, R., Joshi, M. C., Almatroudi, A., Rahmani, A. H., & Ali, S. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.588409 · Cited by 34
Kumar, S. U., Priya, N. M., Nithya, S., Kannan, P., Jain, N., Kumar, D. T., Magesh, R., Younes, S. N., Zayed, H., & Doss, C. G. P. (2021) · 3 Biotech · doi:10.1007/s13205-021-02749-0 · Cited by 36
The Role of Deubiquitinases in Virus Replication and Host Innate Immune Response
Zhang, Q., Jia, Q., Gao, W., & Zhang, W. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.839624 · Cited by 34
Proteases of SARS Coronaviruses
Mukherjee, R., & Đikić, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00111-5 · Cited by 33
“Earlier studies on SARS-CoV showed an inhibition of IRF3 phosphorylation (Devaraj et al., 2007; Matthews et al., 2014).”
Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us
Kumar, V. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1800688 · Cited by 30
“Also, SARSCoV PLpro inhibits the type 1 IFN release in response to RLR, MDA5, and TLR3-mediated activation of IRF3 via directly interacting with it, inhibiting its phosphorylation, and nuclear translocation (Figure 3) [287].”
BackgroundLi, X., & Song, Y. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103832 · Cited by 28
Hu, X., Tian, J., Kang, H., Guo, D., Liu, J., Liu, D., Jiang, Q., Li, Z., Qu, J., & Qu, L. (2017) · BioMed Research International · doi:10.1155/2017/7089091 · Cited by 27
“HCoV-NL63 (PL2-TM) and SARS-CoV (PLpro-TM) inhibit STING-mediated activation of IRF-3 nuclear translocation and induction of IRF-3-dependent promoters [6, 8] .”
BackgroundQuarleri, J. F., & Delpino, M. V. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.01.003 · Cited by 29
“nsp1, ORF 3b, and ORF 6 proteins that block transcription of ISGs [67, 68].”
Host Immune Responses to SARS Coronavirus in Humans
Li, C. K.-F., & Xu, X. (2009) · Springer eBooks · doi:10.1007/978-3-642-03683-5_16 · Cited by 28
“Such inhibition of the IFN response is independent of the protease activity of PLpro (Devaraj et al. 2007).”
BackgroundThe Molecular Interplay between Human Coronaviruses and Autophagy
Shroff, A., & Nazarko, T. Y. (2021) · Cells · doi:10.3390/cells10082022 · Cited by 28
“The NSP3 contains the papain-like protease (PLpro) and transmembrane (TM) domains [18,20].”
BackgroundCOVID-19: Physiopathology and Targets for Therapeutic Intervention
de Almeida, J. O., de Oliveira, V. R. T., Avelar, J. L. D. S., Moita, B. S., & Lima, L. M. (2020) · Revista Virtual de Química · doi:10.21577/1984-6835.20200115 · Cited by 62
Shalash, A. O., Hussein, W. M., Skwarczyński, M., & Tóth, I. (2021) · Advanced Science · doi:10.1002/advs.202100985 · Cited by 28
Role of Virally-Encoded Deubiquitinating Enzymes in Regulation of the Virus Life Cycle
Proulx, J. M., Borgmann, K., & Park, I.-W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094438 · Cited by 24
“Further studies confirmed that this domain of SARS-CoV-1 indeed harbors both a protease and DUB activity [116–118], targeting both Ub and ISG15 to antagonize the induction of type I IFN to inhibit innate immunity [87,116,117,119,120].”
BackgroundShi, X., Zhang, G., Wang, L., Li, X., Zhi, Y., Wang, F., Fan, J., & Deng, R. (2011) · DNA and Cell Biology · doi:10.1089/dna.2010.1188 · Cited by 25
“Over-expression of RIG-N (the constitutively active caspase recruitment domain in RIG-I) (Yoneyama et al. , 2004), VISA, TRIF, TBK1, or IKK-e could induce the activation of IRF-3 and activate the IFN-b promoter (Yoneyama et al. , 2004; Devaraj et al. , 2007; Zhong et al. , 2008).”
InfluentialLin, S., Li, Y., Chen, Y.-T., Chen, T.-C., Hu, C. J., & Chen, H. (2016) · Scientific Reports · doi:10.1038/srep37725 · Cited by 27
“Many coronaviruses have the ability to evade detection by the host's immune system and disrupt the host immune response through multiple mechanisms [32] [33] [34] .”
BackgroundStructural and biochemical characterization of SADS‐CoV papain‐like protease 2
Wang, L., Hu, W., & Fan, C. (2020) · Protein Science · doi:10.1002/pro.3857 · Cited by 23
Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium
Parke, H. G., Linden, D. A., Weldon, S., Kidney, J. C., & Taggart, C. C. (2022) · Medicina · doi:10.3390/medicina58010121 · Cited by 24
Senćanski, M., Perović, V., Milićević, J. S., Todorović, T. R., Prodanović, R., Veljković, V., Paessler, S., & Glišić, S. (2022) · ChemistryOpen · doi:10.1002/open.202100248 · Cited by 23
“resulting in inhibition of the host antiviral innate immune response [9,10].”
BackgroundDang, F., Bai, L., Dong, J., Hu, X., Wang, J., Paulo, J. A., Xiong, Y., Liang, X., Sun, Y., Chen, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh7668 · Cited by 25
“It is known that the PLpro of severe acute respiratory syndrome coronavirus (SARS-CoV) plays crucial roles in protecting the virus against host immune surveillance through removing ubiquitin and ISG15 conjugates from host proteins ( 22 , 47 ).”
BackgroundHost and Viral Zinc-Finger Proteins in COVID-19
Esposito, S., D’Abrosca, G., Antolak, A., Pedone, P. V., Isernia, C., & Malgieri, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073711 · Cited by 23
Time Series Analysis of SARS-CoV-2 Genomes and Correlations among Highly Prevalent Mutations
Periwal, N., Rathod, S. B., Sarma, S., Johar, G. S., Jain, A., Barnwal, R. P., Srivastava, K. R., Kaur, B., Arora, P., & Sood, V. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01219-22 · Cited by 25
“The Nsp3 protein in coronaviruses has been shown to antagonize the innate immune responses [40].”
BackgroundExpression and Functions of SARS Coronavirus Replicative Proteins
Ulferts, R., Imbert, I., Canard, B., & Ziebuhr, J. (2009) · Springer eBooks · doi:10.1007/978-3-642-03683-5_6 · Cited by 22
“was shown to inhibit IFN signaling by binding to IRF-3 and interfering with its hyperphosphorylation, dimerization and nuclear translocation (Devaraj et al. 2007).”
BackgroundThe Role of Coronavirus RNA-Processing Enzymes in Innate Immune Evasion
Mandilara, G. D., Koutsi, M. A., Agelopoulos, M., Sourvinos, G., Beloukas, A. I., & Rampias, T. N. (2021) · Life · doi:10.3390/life11060571 · Cited by 25
“Similarly, studies in SARSCoV have demonstrated that Nsp3 inhibits phosphorylation and nuclear translocation of IRF3-inhibiting IFN signaling [60].”
BackgroundWang, Y., Wu, M., Li, Y., Yuen, H. H., & He, M. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00811-4 · Cited by 28
Kulandaisamy, R., Kushwaha, T., Dalal, A., Kumar, V., Singh, D., Baswal, K., Sharma, P., Praneeth, K., Jorwal, P., Kayampeta, S. R., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.877813 · Cited by 22
Experimental Animal Models of Coronavirus Infections: Strengths and Limitations
Casel, M. A. B., Rollon, R., & Choi, Y. K. (2021) · Immune Network · doi:10.4110/in.2021.21.e12 · Cited by 22
“For example, studies showed that non-structural proteins of coronaviruses impede the host innate immune response, and especially IFN signaling pathways (20-24).”
BackgroundMa, P., Gu, K., Li, H., Zhao, Y. W., Li, C., Wen, R., Zhou, C., Lei, C., Yang, X., & Wang, H. (2022) · Viruses · doi:10.3390/v14051045 · Cited by 21
Therapies for coronaviruses. Part 2: inhibitors of intracellular life cycle
Tong, T. R. S.-W. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770802600698 · Cited by 23
“IFN-regulatory factor 3 (IRF-3), a latent transcription factor downstream of the pathogen pattern recognition receptors, is prevented from phosphorylation and nuclear translocation by SARSCoV PLpro [54].”
BackgroundCoronavirus in Continuous Flux: From SARS‐CoV to SARS‐CoV‐2
Dong, Y., Dai, T., Liu, J., Zhang, L., & Zhou, F. (2020) · Advanced Science · doi:10.1002/advs.202001474 · Cited by 20
Sarafeddinov, A., Arif, A., Peters, A., & Fuchsbauer, H. (2011) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1012.12004 · Cited by 21
Ma, X., Bartczak, A. M., Zhang, J., He, W., Shalev, I., Smil, D. V., Chen, L., Phillips, J., Feld, J. J., Selzner, N., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03801-13 · Cited by 19
Razali, R., Subbiah, V. K., & Budiman, C. (2021) · Data · doi:10.3390/data6090099 · Cited by 19
Reducing SARS-CoV-2 pathological protein activity with small molecules
Pluskota‐Karwatka, D., Hoffmann, M., & Barciszewski, J. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.03.012 · Cited by 18
“This action is perceived as a mechanism to avoid the host's antiviral immune response [62,63].”
In silico analysis of SARS-CoV-2 papain-like protease potential inhibitors
Elseginy, S. A., & Anwar, M. M. (2021) · RSC Advances · doi:10.1039/d1ra07845c · Cited by 18
“23,24 In addition to proteolytic activity of PLpro to the viral proteins PP1a and PP1b, it plays an essential role in the inhibition of the innate immune response of the host.”
Ferreira, J. C., Villanueva, A. J., Adem, K. A., Fadl, S., Alzyoud, L., Ghattas, M. A., & Rabeh, W. M. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107821 · Cited by 19
Li, J., Zhou, Z., Wang, Q., He, Q., Zhao, M., Qiu, Y., & Ge, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.770656 · Cited by 18
Escape and Over-Activation of Innate Immune Responses by SARS-CoV-2: Two Faces of a Coin
Mattoo, S.-U.-S., Kim, S., Ahn, D., & Myoung, J. (2022) · Viruses · doi:10.3390/v14030530 · Cited by 21
“SARS-CoV-1 and SARS-CoV-2 NSP3 can bind IRF3 and prevent its phosphorylation, dimerization, or translocation to the nucleus, effectively inhibiting type I IFN synthesis [69].”
BackgroundDifferences and similarities between innate immune evasion strategies of human coronaviruses
Hoenigsperger, H., Sivarajan, R., & Sparrer, K. M. J. (2024) · Current Opinion in Microbiology · doi:10.1016/j.mib.2024.102466 · Cited by 20
The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2
Aliyari, S. R., Quanquin, N. M., Pernet, O., Zhang, S., Wang, L., & Cheng, G. (2022) · Pathogens · doi:10.3390/pathogens11050538 · Cited by 20
“nsp2 IRF3 prevents phosphorylation SARS-CoV-1 [126]”
Sun, X., Quan, L., Chen, R., & Liu, D. X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911692 · Cited by 17
“Coronavirus nsp3 is implicated in cleaving proteinaceous post-translational modifications on host proteins as an evasion mechanism against host antiviral immune responses [12,29].”
BackgroundInfluentialKattula, B., Reddi, B., Jangam, A., Naik, L., Adimoolam, B. M., Suresh, V., Are, S., Thota, J. R., Jadav, S. S., Arifuddin, M., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124772 · Cited by 20
Antiviral Effect of Selenomethionine on Porcine Deltacoronavirus in Pig Kidney Epithelial Cells
Ren, Z., Jia, G., He, H., Ding, T., Yu, Y., Zuo, Z., Hu, Y., Zhong, Z., Yu, S., Deng, H., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.846747 · Cited by 16
Latifi-Pupovci, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113368 · Cited by 19
“On the other hand, structural protein N (nucleocapsid) inhibits IRF3 activation and consequently type-I IFN production in the early PRR recognition stage of the signaling pathways [96] and also through suppression of RIG-I ubiquitination and activation [52].”
InfluentialErshov, P. V., Yablokov, E. O., Mezentsev, Y. V., Chuev, G. N., Fedotova, M. V., Kruchinin, S. E., & Ivanov, A. S. (2022) · BIOPHYSICS · doi:10.1134/s0006350922060082 · Cited by 19
High-Throughput Fluorescent Assay for Inhibitor Screening of Proteases from RNA Viruses
Cihlova, B., Hušková, A., Böserle, J., Nencka, R., Bouřa, E., & Šilhán, J. (2021) · Molecules · doi:10.3390/molecules26133792 · Cited by 15
“Moreover, the inhibition of the PL enzyme from other coronaviruses has been demonstrated to suppress viral replication [10-12].”
BackgroundHidayah, N. A., & Swastika, P. (2022) · Journal of Islamic Monetary Economics and Finance · doi:10.21098/jimf.v8i4.1483 · Cited by 17
Reprogramming viral immune evasion for a rational design of next-generation vaccines for RNA viruses
Su, C.-M., Du, Y., Rowland, R. R. R., Wang, Q., & Yoo, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172000 · Cited by 15
“The nsp1 protein of SARS-CoV-1 suppresses the IFN response via IRF3-dependent downregulation (85, 86), whereas the ORF8b and ORF8ab proteins induce IRF3 degradation via the ubiquitin-dependent proteasomal pathway (87).”
BackgroundRegla-Nava, J. Á., Jiménez-Guardeño, J. M., Nieto-Torres, J. L., Gallagher, T. M., Enjuanes, L., & DeDiego, M. L. (2013) · Journal of Virological Methods · doi:10.1016/j.jviromet.2013.07.039 · Cited by 17
“In fact, SARS-CoV roteins nsp1, nsp3, 3b, 6, M and N act as interferon antagoists (Devaraj et al., 2007; Frieman et al., 2007; Kopecky-Bromberg t al., 2007; Narayanan et al., 2008; Siu et al., 2009; Sun et al., 012; Wathelet et al., 2007).”
BackgroundDampak Penerapan PSBB Covid-19 dan Harga Saham LQ-45 di Bursa Efek Indonesia (BEI)
Jecuinna, P., & Zielma, A. (2021) · JEMMA (Journal of Economic Management and Accounting) · doi:10.35914/jemma.v4i2.736 · Cited by 14
In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D
Protić, S., Kaličanin, N., Senćanski, M., Prodanović, O., Milićević, J. S., Perović, V., Paessler, S., Prodanović, R., & Glišić, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031955 · Cited by 14
“PLpro is a monomer with a canonical catalytic triad of Cys111/His272/Asp286 at its active site [2,3].”
BackgroundChen, Y., Hsu, H.-C., Wang, S.-W., Lien, H.-C., Lu, H.-T., & Peng, S.-K. (2019) · Pathogens · doi:10.3390/pathogens8040259 · Cited by 13
“Viral proteins, in particular nsp1 [44] , nsp3 [45] , N protein and the SARS-CoV accessary protein ORF6, ORF3b [46] , and ORF4a [47] , prevent IFN induction.”
BackgroundSARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
Mohammed, M. E. A. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666210223143243 · Cited by 13
Shi, X., Zhang, X., Wang, F., Wang, L., Qiao, S., Guo, J., Luo, C.-H., Wan, B., Deng, R., & Zhang, G. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0100 · Cited by 13
Wang, X., & Christopher‐Hennings, J. (2012) · Viruses · doi:10.3390/v4050725 · Cited by 14
“In addition to IRF-3, interferon regulatory factor -7 (IRF-7) also plays some role in the late phase of interferon- and induction [11].”
Yang, T., Wang, S. C., Ye, L., Maimaitiyiming, Y., & Naranmandura, H. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2175812 · Cited by 13
A pocket guide on how to structure SARS-CoV-2 drugs and therapies
Littler, D. R., MacLachlan, B. J., Watson, G. M., Vivian, J. P., & Gully, B. S. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200396 · Cited by 13
SARS-CoV-2 3CLpro whole human proteome cleavage prediction and enrichment/depletion analysis
Prescott, L. (2022) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2022.107671 · Cited by 14
“[25-29] PLpro deubiquination also prevents activating 67 phosphorylation of interferon regulatory factor 3 (IRF3) and subsequent type-I interferon 68 production,[30, 31] however the ubiquitinated leucine in human IRF3 is replaced by a serine in bats 69 likely including Rhinolophus affinus (intermediate horseshoe bat),…”
BackgroundOjha, N. K., Liu, J., Yu, T., Fang, C., Zhou, J., & Liao, M. (2021) · Archives of Virology · doi:10.1007/s00705-021-05073-3 · Cited by 14
Molecular Insights into Small‐Molecule Drug Discovery for SARS‐CoV‐2
Su, H., Zhou, F., Huang, Z., Ma, X., Natarajan, K., Zhang, M., Huang, Y., & Su, H. (2021) · Angewandte Chemie · doi:10.1002/ange.202008835 · Cited by 13
Yang, M., Mariano, J. M., Su, R., Smith, C. E., Das, S., Gill, C., Andrésson, Þ., Lončarek, J., Tsai, Y. C., & Weissman, A. M. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105346 · Cited by 12
“In several studies examining either transmembrane or soluble cytoplasmic SARS-CoV-1 PLpro, attenuation of the IFN response was found to be independent of PLpro catalytic activity and attributed to disruption of protein – protein interactions (20 – 23).”
BackgroundRoy, R., Jonniya, N. A., Poddar, S., Sk, M. F., & Kar, P. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00918 · Cited by 11
Rajak, P., & Ganguly, A. (2023) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2023.100015 · Cited by 11
“It is also implicated in proteinous post-translational modi fi cations via deubiquitinating and deISGylating effects that are required to evade host's defense mechanism [45].”
Natural Products as Potential Therapeutic Agents for SARS-CoV-2: A Medicinal Chemistry Perspective
Aggarwal, V., Bala, E., Kumar, P., Raizada, P., Singh, P., & Verma, P. K. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230327125918 · Cited by 12
Shetler, C. L., Ferreira, J. C., Cardoso, T. H. S., Silva, E. M. A., Saksena, N. K., & Rabeh, W. M. (2022) · Biochemical Journal · doi:10.1042/bcj20220380 · Cited by 10
Viral Ubiquitin and Ubiquitin-Like Deconjugases—Swiss Army Knives for Infection
Masucci, M. G. (2020) · Biomolecules · doi:10.3390/biom10081137 · Cited by 11
“The deconjugase activity of CoV PLpro has been implicated in the downregulation of innate immune responses [145,146].”
BackgroundRibone, S. R., Paz, S. A., Abrams, C. F., & Villarreal, M. A. (2021) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-021-00432-3 · Cited by 10
Insights into the modulation of the interferon response and NAD+in the context of COVID-19
Habeichi, N. J., Tannous, C., Yabluchanskiy, A., Altara, R., Mericskay, M., Booz, G. W., & Zouein, F. A. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1961768 · Cited by 11
Interferon interplay helps tissue cells to cope with SARS-Coronavirus infection
Kuri, T., & Weber, F. (2010) · Virulence · doi:10.4161/viru.1.4.11465 · Cited by 9
Tarasova, O. A., Petrou, A., Ivanov, S. M., Geronikaki, A. A., & Poroikov, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179408 · Cited by 10
“Most of these mechanisms are associated with the inhibition of signaling pathways involved in viral replication in host cells and with the influence on some other cascades that control interferon production [2–5].”
BackgroundYusuf, A. J., Abdullahi, M. I., Musa, A. M., Abubakar, H., Muhammad, A. A., & Hamza, A. (2021) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2021.57527 · Cited by 9
Homma, T., Ishibashi, D., Nakagaki, T., Fuse, T., Sano, K., Satoh, K., Atarashi, R., & Nishida, N. (2014) · Scientific Reports · doi:10.1038/srep06006 · Cited by 9
“Interestingly, it has also been reported that infection by some viruses enhances the degradation of IRF-3 and/or inhibits its phosphorylation, resulting in the reduced response of IFN-I production and persistent infection by the virus [2] [3] [4] [5] [6] [7] .”
BackgroundDurie, I. A., Dzimianski, J. V., Daczkowski, C. M., McGuire, J. R., Faaberg, K. S., & Pegan, S. D. (2021) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s205979832100509x · Cited by 9
Li, K., Shen, Y., Miller, M. A., Stabenow, J., Williams, R. W., & Lu, L. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00656-8 · Cited by 9
Self-citationViral deubiquitinating proteases and the promising strategies of their inhibition
van Vliet, V. J. E., Silva, A. D., Mark, B. L., & Kikkert, M. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199368 · Cited by 8
“An overall DUB effect of PLpro was confirmed by Frieman et al. (2009), who also showed that the protease inhibited IFN-β promoter activation after poly I:C and SeV induction, similar to what Devaraj et al. (2007) had shown previously.”
ResultZhang, P., Yu, L., Dong, J., Liu, Y., Zhang, L., Liang, P., Wang, L., Chen, B., Huang, L., & Song, C. (2020) · Veterinary Microbiology · doi:10.1016/j.vetmic.2020.108793 · Cited by 8
Kehrer, T., García‐Sastre, A., & Miorin, L. (2021) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2021.0060 · Cited by 9
Freitas, B. T., Ahiadorme, D. A., Bagul, R. S., Durie, I. A., Ghosh, S., Hill, J., Kramer, N. E., Murray, J., O’Boyle, B. M., Onobun, E., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00631 · Cited by 9
Choudhary, S., Nehul, S., Nagaraj, S. K., Narayan, R., Verma, S., Sharma, S., Kumari, A., Rani, R., Saha, A., Sircar, D., et al. (2026) · FEBS Journal · doi:10.1111/febs.70399 · Cited by 8
Kurt‐Jones, E. A., Dudek, T. E., Watanabe, D., Mandell, L., Che, J., Zhou, S., Cao, L.-C., Greenough, T. C., Babcock, G. J., Diaz, F., et al. (2021) · Virology · doi:10.1016/j.virol.2021.04.006 · Cited by 8
“SARS-CoV-1 is known to inhibit type 1 interferon signaling by blocking IRF-3 and NF-κB signaling (Devaraj et al., 2007; Frieman et al., 2009) by the action of several proteins (Perlman and Masters, 2020), but the mechanism(s) of induction of pro-inflammatory cytokines have not been defined.”
Chu, H.-F., Cheng, S.-C., Sun, C.-Y., Chou, C.-Y., Lin, T.-H., & Chen, W.-Y. (2021) · Journal of Virology · doi:10.1128/jvi.01372-21 · Cited by 8
Metadata
- Authors
- Devaraj, S. G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C. J., Tseng, C.-T. K., Baker, S. C., & Li, K.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- Loyola University Chicago (US)
- Lady Davis Institute for Medical Research (CA)
- Corresponding author
- Li, Kui
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 282
- Issue
- 44
- Pages
- 32208-32221
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC2756044
- OpenAlex
- W190626844
- Cited by
- 411
- References
- 80
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 14 · 2023: 17 · 2022: 37 · 2021: 72 · 2020: 71 · 2019: 9 · 2018: 5 · 2017: 14 · 2016: 9 · 2015: 9 · 2014: 30 · 2013: 18 · 2012: 13
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4687 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01ai30039-19-0-2)
- National Institute on Drug Abuse (DA-018054, R21DA018054)
- National Institute of Allergy and Infectious Diseases (P01AI060915, AI060915, AI30039, AI-069285, AI 45798, AI057156, N01-AI-030039, U54AI057156, R01AI069285, R01AI045798)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- SARS-CoV, IRF3, papain-like protease, type I interferon, innate immune evasion, interferon antagonism, IRF3 phosphorylation, TLR3, IFN-stimulated genes, lung epithelial cells, viral pathogenesis
- MeSH terms
- Animals, Bronchi, Cell Line, Humans, Immunity, Innate, Interferon Type I, Peptide Hydrolases, Viral Proteins, Protein Structure, Tertiary, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Interferon Regulatory Factor-3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.